Daniel Aletaha
A5061411814- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Psoriasis: Treatment and Pathogenesis
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Immunology Research
- Peripheral Neuropathies and Disorders
- Musculoskeletal synovial abnormalities and treatments
- Health Systems, Economic Evaluations, Quality of Life
- Osteoarthritis Treatment and Mechanisms
- Cytokine Signaling Pathways and Interactions
- HER2/EGFR in Cancer Research
- Musculoskeletal Disorders and Rehabilitation
- Statistical Methods in Clinical Trials
- Chronic Myeloid Leukemia Treatments
- COVID-19 Clinical Research Studies
- Systemic Sclerosis and Related Diseases
- Inflammasome and immune disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Vasculitis and related conditions
Medical University of Vienna
2016-2025
Swedish Medical Center
2024
AbbVie (United States)
2024
University of California, San Diego
2024
Nippon Medical School Hospital
2024
Griffith University
2024
Center for Rheumatology
2001-2023
Universitätszahnklinik Wien
2012-2023
University of Amsterdam
2016-2023
University of Padua
2022
The 1987 American College of Rheumatology (ACR; formerly, the Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized their lack sensitivity in early disease. This work was undertaken to develop new RA.A joint working group from ACR and European League Against developed, 3 phases, a approach classifying RA. focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between...
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs bDMARDs, respectively) have been updated. The 2013 update has developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each sDMARDs, including glucocorticoids, bDMARDs safety aspects DMARD therapy); treatment...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
This criteria set has been approved by the American College of Rheumatology (ACR) Board Directors and European League Against Rheumatism (EULAR) Executive Committee as Provisional.This signifies that quantitatively validated using patient data, but it not undergone validation based on an external data set.All ACR/EULAR-approved sets are expected to undergo intermittent updates.The is independent, professional, medical scientific society which does guarantee, warrant, or endorse any...
Abstract Introduction Frequent assessments of rheumatoid arthritis (RA) disease activity allow timely adaptation therapy, which is essential in preventing progression. However, values acute phase reactants (APRs) are needed to calculate current composite indices, such as the Disease Activity Score (DAS)28, DAS28-CRP (i.e. DAS28 using C-reactive protein instead erythrocyte sedimentation rate) and Simplified Index (SDAI). We hypothesized that APRs make limited contribution SDAI, an...
Background Since the publication of European League Against Rheumatism recommendations for pharmacological treatment psoriatic arthritis (PsA) in 2012, new evidence and therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review performed regarding PsA. Subsequently, were formulated based on expert opinion 34 Task Force members. Levels strengths allocated. Results updated comprise 5 overarching principles 10 recommendations,...
Objective: To validate and compare the definition of Disease Activity Score 28 based on C-reactive protein (DAS28 (CRP)) to erythrocyte sedimentation rate (ESR). Methods: Data were analysed from two randomised, double-blind, placebo-controlled trials abatacept 6-month 12-month duration in patients with rheumatoid arthritis. European League Against Rheumatism (EULAR) response criteria proportion remission <2.6) DAS28 definitions examined. Trends radiographic progression (erosion score, joint...
Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there no widely used definition of remission that stringent achievable and could be applied uniformly as outcome measure clinical trials. This work was undertaken to develop such a definition. Methods A committee consisting members the American College Rheumatology, European League Against Rheumatism, Outcome Measures Rheumatology Initiative met guide process review prespecified analyses from RA The...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence these recommendations was only of indirect nature. These were re-evaluated light new insights. Based on results a systematic literature review expert opinion, task force rheumatologists, dermatologists, patients health professional developed an update 2012 recommendations. underwent intensive discussions, site voting subsequent anonymous electronic levels agreement with each item....
Abstract Objective Several composite scores are available to assess the activity of rheumatoid arthritis (RA). Criteria for remission and active RA based on these continuous important use in clinical practice trials. We aimed reevaluate or define such criteria Disease Activity Score 28 joints (DAS28) Simplified Index (SDAI). Methods sampled patient profiles from an observational database that included laboratory variables. Thirty‐five rheumatology experts classified into 1 4 categories:...
<h3>Objectives</h3> Since the 2007 recommendations for management of early arthritis have been presented, considerable research has published in field arthritis, mandating an update European League Against Rheumatism (EULAR) arthritis. <h3>Methods</h3> In accordance with 2014 EULAR Standardised Operating Procedures, expert committee pursued approach that was based on evidence literature and opinion. The involved 20 rheumatologists, 2 patients 1 healthcare professional representing 12...
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods are based evidence from systematic literature reviews performed non-steroidal anti-inflammatory (NSAID),...
The Disease Activity Index for Psoriatic Arthritis (DAPSA) is a valid and discriminative tool. Definitions of disease activity states therapeutic response are still missing. We derived such criteria the DAPSA.We retrieved 30 patient profiles from an observational database including joint counts, pain global ratings C-reactive protein (CRP) carried out survey among experts to classify patients into remission (REM), low (LDA), moderate (MDA) or high (HDA) activity. Based on distributions DAPSA...
Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These can be considered have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking.The Task Force in charge "Development EULAR recommendations for comprehensive difficult-to-treat arthritis" aims create this underserved patient group. Herein, we present RA, as first step.The Steering Committee...